DDInter147 DDInter1658
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Axitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lansoprazole
Axitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium citrate
Axitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Axitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Netupitant
Axitinib {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Axitinib {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Axitinib may cause a minor interaction that can limit clinical effects when taken with Lansoprazole
Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Axitinib may lead to a major life threatening interaction when taken with Atazanavir
Axitinib may lead to a major life threatening interaction when taken with Lomitapide